Penpulimab
- Generic Name
- Penpulimab
- Drug Type
- Biotech
- CAS Number
- 2350298-92-7
- Unique Ingredient Identifier
- IBS1BZ4E4I
- Indication
适用于至少经过二线系统化疗的复发或难治性经典型霍奇金淋巴瘤成人患者。
A Phase III Study to Evaluate the Efficacy and Safety of Penpulimab in the Relapsed and Refractory Classical Hodgkin's Lymphoma
- Conditions
- Hodgkin Disease Lymphoma
- Interventions
- Drug: Investigator's choice of Chemotherapy
- First Posted Date
- 2022-02-17
- Last Posted Date
- 2022-02-17
- Lead Sponsor
- Akeso
- Target Recruit Count
- 60
- Registration Number
- NCT05244642
- Locations
- 🇨🇳
Affiliated Cancer Hospital and Institute of Guangzhou Medical University, Guangzhou, Guangdong, China
🇨🇳Xiangya Hospital Central South University, Changsha, Hunan, China
🇨🇳Qilu Hospital of Shandong University, Jinan, Shandong, China
AK105 Plus Anlotinib Hydrochloride Combined With Albumin Paclitaxel as a First-line Therapy in Patients With Advanced Triple-negative Breast Cancer
- Conditions
- Breast Neoplasm Female
- Interventions
- First Posted Date
- 2022-02-17
- Last Posted Date
- 2022-07-12
- Lead Sponsor
- Liaoning Tumor Hospital & Institute
- Target Recruit Count
- 42
- Registration Number
- NCT05244993
Irinotecan Plus Anlotinib or Further in Combination With Penpulimab for Second-line Treatment of mCRC
- Conditions
- Metastatic Colorectal Cancer
- Interventions
- First Posted Date
- 2022-02-08
- Last Posted Date
- 2024-07-03
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 44
- Registration Number
- NCT05229003
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
Study of AK105 With Anlotinib and Radiotherapy Adjuvant Therapy in MGMT Unmethylated Newly Diagnosed Glioblastoma.
- Conditions
- MGMT-Unmethylated Glioblastoma
- Interventions
- First Posted Date
- 2021-09-05
- Last Posted Date
- 2021-09-05
- Lead Sponsor
- The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
- Target Recruit Count
- 28
- Registration Number
- NCT05033587
- Locations
- 🇨🇳
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School, Nanjing, Jiangsu, China
A Phase II Study of Anlotinib Combined With Penpulimab in Subjects With Gynecological Cancer
- First Posted Date
- 2021-08-31
- Last Posted Date
- 2023-12-27
- Lead Sponsor
- Sichuan Cancer Hospital and Research Institute
- Target Recruit Count
- 86
- Registration Number
- NCT05028504
- Locations
- 🇨🇳
Shaanxi Provincial Cancer Hospital, Xi'an, Shanxi, China
🇨🇳Sicchuan cancer hospital, Chengdu, Sichuan, China
🇨🇳The First Affiliated Hospital of USTC, Anhui Provincial Hospital, Hefei, Hefei, China
A Study of Penpulimab (AK105) in the First-line Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma
- Conditions
- Nasopharyngeal Carcinoma
- Interventions
- Drug: placebo
- First Posted Date
- 2021-07-23
- Last Posted Date
- 2025-04-13
- Lead Sponsor
- Akeso
- Target Recruit Count
- 296
- Registration Number
- NCT04974398
- Locations
- 🇧🇷
Grupo Oncoclínicas, Botafogo, Reg1, Brazil
🇧🇷Hospital Bruno Born, Lajeado, Reg1, Brazil
🇺🇸City of Hope, Duarte, California, United States
Anlotinib Plus Penpulimab (AK105) for Chemo-refractory Metastatic Colorectal Cancer:ALTER-C003
- First Posted Date
- 2021-07-21
- Last Posted Date
- 2022-03-08
- Lead Sponsor
- Peking Union Medical College Hospital
- Target Recruit Count
- 32
- Registration Number
- NCT04970914
- Locations
- 🇨🇳
Beijing Tiantan Hospital, Capital Medical University, Beijing, Beijing, China
🇨🇳China-Japan friendship hospital, Beijing, Beijing, China
🇨🇳Hebei Petro China Central Hospital, Langfang, Hebei, China
Anlotinib or Penpulimab in Combination With RAI for DTC
- Conditions
- Thyroid Cancer
- Interventions
- First Posted Date
- 2021-07-07
- Last Posted Date
- 2022-01-28
- Lead Sponsor
- Peking Union Medical College Hospital
- Target Recruit Count
- 42
- Registration Number
- NCT04952493
- Locations
- 🇨🇳
Peking Union Medical College Hospital, Beijing, China
A Study of Penpulimab Combination Therapy in Patients With Advanced Nasopharyngeal Carcinoma
- Conditions
- Nasopharyngeal Carcinoma
- Interventions
- First Posted Date
- 2021-02-03
- Last Posted Date
- 2025-03-07
- Lead Sponsor
- Akeso
- Target Recruit Count
- 28
- Registration Number
- NCT04736810
- Locations
- 🇨🇳
Cancer Hospital of the University of Chinese Academy of Sciences, Hangzhou, Zhejiang, China
A Study of Anlotinib Combined With AK105 Injection in Subjects With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Advanced Solid Tumor
- First Posted Date
- 2020-03-02
- Last Posted Date
- 2020-03-02
- Lead Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Target Recruit Count
- 138
- Registration Number
- NCT04291248
- Locations
- 🇨🇳
Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, Beijing, China
🇨🇳The Second Affiliated Hospital of The PLA Air Force Medical University, Xi'an, Shanxi, China
🇨🇳Jiangsu Cancer Hospital, Nanjing, Jiangsu, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.